Use of a Four-miRNA Panel As a Biomarker for the Diagnosis of Stomach Adenocarcinoma

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2020 Nov 23

PMID 33224315

Citations 10

Authors

Xuan Chen

Xinji Li

Xiqi Peng

Chunduo Zhang

Kaihao Liu

Guocheng Huang

Yongqing Lai

Affiliations

Soon will be listed here.

Abstract

Background: MicroRNAs (miRNAs) have been applied to cancer diagnosis taking into account their role in tumorigenesis. The main purpose of our study was to confirm the possibility of using miRNAs as noninvasive biomarkers for stomach adenocarcinoma (STAD) diagnosis.

Methods: A total of 246 participants (130 STAD patients and 116 healthy controls (HCs)) were enrolled in this 3-phase study. Five STAD pools and 3 HC pools (with 4 participants in each pool) were used for the screening of the 28 miRNAs using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The training phase (30 STAD patients vs. 24 HCs) and validation phase (80 STAD patients vs. 80 HCs) were used to further verify the identity of these miRNAs. Kaplan-Meier survival analysis and bioinformatics analysis were also used.

Results: The expression levels of miR-125b-5p and miR-196a-5p were upregulated in STAD serum, compared with the HCs, while miR-1-3p and miR-149-5p showed the opposite result. A four-serum miRNA panel was constructed, and the area under the receiver operating characteristic curve (AUC) was found to be 0.892 (95% CI: 0.834 to 0.936, sensitivity = 86.25%, specificity = 78.75%). Only miR-125b-5p expression showed a significant difference between STAD patients and NCs in the survival analysis. The neurotrophin signaling pathway was associated with 4 miRNAs identified in STAD patients.

Conclusion: The four-serum miRNA panel has great potential to be used as a noninvasive biomarker for STAD diagnosis.

Citing Articles

Cell-free Nucleic Acid as Promising Diagnostic Biomarkers for Gastric Cancer: a Systematic Review.

Zhang Q, Du Z, Wang X, Li F, Liu Y, Sun J J Cancer. 2024; 15(10):2900-2912.

PMID: 38706900 PMC: 11064260. DOI: 10.7150/jca.92704.

The important role of miR-1-3p in cancers.

Dai S, Li F, Xu S, Hu J, Gao L J Transl Med. 2023; 21(1):769.

PMID: 37907984 PMC: 10617136. DOI: 10.1186/s12967-023-04649-8.

Angiotensinogen, a promising gene signature for rectum and stomach adenocarcinoma patients.

Hu W, Abdel-Maksoud M, Khalid S, Malik A, Alkholief M, Mubarak A Am J Transl Res. 2023; 14(12):8879-8892.

PMID: 36628228 PMC: 9827296.

Tumor-Suppressive and Oncogenic Roles of microRNA-149-5p in Human Cancers.

Shen Y, Zhao N, Hu X, He X, Xu Y, Chen J Int J Mol Sci. 2022; 23(18).

PMID: 36142734 PMC: 9501226. DOI: 10.3390/ijms231810823.

Identification of miRNA biomarkers for stomach adenocarcinoma.

Qian H, Cui N, Zhou Q, Zhang S BMC Bioinformatics. 2022; 23(1):181.

PMID: 35578189 PMC: 9112558. DOI: 10.1186/s12859-022-04719-6.

References

Karimi P, Islami F, Anandasabapathy S, Freedman N, Kamangar F . Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014; 23(5):700-13. PMC: 4019373. DOI: 10.1158/1055-9965.EPI-13-1057. View

Gareev I, Beylerli O, Yang G, Sun J, Pavlov V, Izmailov A . The current state of MiRNAs as biomarkers and therapeutic tools. Clin Exp Med. 2020; 20(3):349-359. DOI: 10.1007/s10238-020-00627-2. View

Zhao X, Liu Y, Zheng J, Liu X, Chen J, Liu L . GAS5 suppresses malignancy of human glioma stem cells via a miR-196a-5p/FOXO1 feedback loop. Biochim Biophys Acta Mol Cell Res. 2017; 1864(10):1605-1617. DOI: 10.1016/j.bbamcr.2017.06.020. View

Kemi N, Eskuri M, Ikalainen J, Karttunen T, Kauppila J . Tumor Budding and Prognosis in Gastric Adenocarcinoma. Am J Surg Pathol. 2018; 43(2):229-234. DOI: 10.1097/PAS.0000000000001181. View

Ma Z, Han C, Xia W, Wang S, Li X, Fang P . circ5615 functions as a ceRNA to promote colorectal cancer progression by upregulating TNKS. Cell Death Dis. 2020; 11(5):356. PMC: 7214456. DOI: 10.1038/s41419-020-2514-0. View

Zhang X, Wang S, Wang H, Cao J, Huang X, Chen Z . Circular RNA circNRIP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR pathway. Mol Cancer. 2019; 18(1):20. PMC: 6360801. DOI: 10.1186/s12943-018-0935-5. View

Martins M, Almeida R, Lucena-Silva N, Coutinho-Camilo C, Torjal I, Santos R . MicroRNA expression profiling provides novel insights into immune-related pathways involved in gastric cancer. Med Oncol. 2019; 36(9):81. DOI: 10.1007/s12032-019-1305-x. View

Ke J, Zhang B, Li Y, Zhong M, Ma W, Xue H . MiR-1-3p suppresses cell proliferation and invasion and targets STC2 in gastric cancer. Eur Rev Med Pharmacol Sci. 2019; 23(20):8870-8877. DOI: 10.26355/eurrev_201910_19282. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

10.

Yasar A, Saritas I, Korkmaz H . Computer-Aided Diagnosis System for Detection of Stomach Cancer with Image Processing Techniques. J Med Syst. 2019; 43(4):99. DOI: 10.1007/s10916-019-1203-y. View

11.

Bustin S, Mueller R . Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis. Clin Sci (Lond). 2005; 109(4):365-79. DOI: 10.1042/CS20050086. View

12.

Zhou X, Wen W, Zhu J, Huang Z, Zhang L, Zhang H . A six-microRNA signature in plasma was identified as a potential biomarker in diagnosis of esophageal squamous cell carcinoma. Oncotarget. 2017; 8(21):34468-34480. PMC: 5470983. DOI: 10.18632/oncotarget.16519. View

13.

Zhang C, Zhang C, Ma M, Dai D . Three-microRNA signature identified by bioinformatics analysis predicts prognosis of gastric cancer patients. World J Gastroenterol. 2018; 24(11):1206-1215. PMC: 5859223. DOI: 10.3748/wjg.v24.i11.1206. View

14.

Chopin V, Lagadec C, Toillon R, Le Bourhis X . Neurotrophin signaling in cancer stem cells. Cell Mol Life Sci. 2016; 73(9):1859-70. PMC: 11108437. DOI: 10.1007/s00018-016-2156-7. View

15.

Xin H, Wang C, Liu Z . miR-196a-5p promotes metastasis of colorectal cancer via targeting IκBα. BMC Cancer. 2019; 19(1):30. PMC: 6325824. DOI: 10.1186/s12885-018-5245-1. View

16.

Iwasaki H, Shimura T, Yamada T, Okuda Y, Natsume M, Kitagawa M . A novel urinary microRNA biomarker panel for detecting gastric cancer. J Gastroenterol. 2019; 54(12):1061-1069. DOI: 10.1007/s00535-019-01601-w. View

17.

Lario S, Brunet-Vega A, Quilez M, Ramirez-Lazaro M, Lozano J, Garcia-Martinez L . Expression profile of circulating microRNAs in the Correa pathway of progression to gastric cancer. United European Gastroenterol J. 2018; 6(5):691-701. PMC: 6068781. DOI: 10.1177/2050640618759433. View

18.

Fitzmaurice C, Akinyemiju T, Al Lami F, Alam T, Alizadeh-Navaei R, Allen C . Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2018; 4(11):1553-1568. PMC: 6248091. DOI: 10.1001/jamaoncol.2018.2706. View

19.

Okugawa Y, Tanaka K, Inoue Y, Kawamura M, Kawamoto A, Hiro J . Brain-derived neurotrophic factor/tropomyosin-related kinase B pathway in gastric cancer. Br J Cancer. 2012; 108(1):121-30. PMC: 3553513. DOI: 10.1038/bjc.2012.499. View

20.

Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View